Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States

Wednesday, December 3, 2008 General News J E 4
MALVERN, Pa., Dec. 2 Arlington Medical Resources (AMR), aprovider of premier market intelligence for the pharmaceutical and diagnosticimaging industries, finds that Ortho-McNeil-Janssen Pharmaceuticals' Levaquinis the preferred quinolone antibiotic among more than half of all generalmedical-surgical hospitals in the United States. Quinolone antibiotics areused to treat lung, sinus, skin and urinary tract infections caused bynumerous bacterial pathogens.

"Based on our October 2008 audit, intravenous Levaquin was stocked in morehospitals than both Bayer's intravenous Cipro and generic intravenousciprofloxacin combined," stated Matthew W. Mahr, Pharm.D., M.B.A., analyst atAMR.

The newly released edition of the Quinolone Monthly Monitor (U.S.) alsofinds that over 70 percent of hospitals reported having a closed hospitalformulary for antibiotics. Large hospitals were found to be most likely tohave a closed formulary for antibiotics. These closed formularies createrestrictions on what can be prescribed in the hospital making it moredifficult for a prescriber to use that medication.

Why Pharmaceutical Companies Need this Information

The Quinolone Monthly Monitor (U.S.) enables pharmaceutical companies tomonitor formulary, stocking and restriction status of selected quinoloneantibiotics. This study also gives information about the Pharmacy andTherapeutics Committee's actions for quinolones, which drive formulary andrestriction status for these products.

About The Quinolone Monthly Monitor (U.S.)

The Quinolone Monthly Monitor (U.S.) is the industry's most comprehensivemarket research study of the formulary status of quinolone antibiotics. Thisstudy has been conducted monthly since June 1992 by collecting data from 300pharmacy directors from a group of demographically representative acute carehospitals within the country.

About AMR

AMR ( serves the market intelligence needs of thepharmaceutical and diagnostic imaging industries. Research includes clinicalinpatient databases that directly link anti-infective drug withindication/procedure, formulary and stocking status tracking studies, drugpurchasing audits and diagnostic imaging procedure volume/contrast media usageaudits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563

SOURCE Arlington Medical Resources


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Neuralstem Collaborates with Hospital in Taiwan to...
Biologic Drugs, Particularly Centocor/Janssen-Cila...